A consortium of sponsors and CROs are beginning to participate in a survey that will not only assess their perceptions of quality but how those perceptions have stacked up over the years.
The Institute of Medicine is conducting a consensus study to recommend guiding principles and a framework for the responsible sharing of clinical trial data before a final report is released in December 2014.
Australia’s largest clinical CRO Novotech has expanded its clinical services with a new office in Johannesburg, South Africa to deal with increasing sponsor demand.
The need to improve efficiency and comply with regulatory and geographical demands is driving the third-party clinical payment industry, say Greenphire, CFS and Clinverse.
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
The new formula Indian regulators will use to calculate compensation for the families of patients who die in trials is confusing, imprecise and needs clarification, according to Outsourcing-pharma.com’s Zachary Brennan.
The six biggest CROs look set to see revenues grow in the next few years with both Parexel and Icon predicting the group will capture a larger share of research spend.
Davita Clinical Research (DCR) has said increasing client demand for adaptive trial designs in early Phase research prompted its partnership with Pacific Pharma Group study expert, Jon Ruckle.
Gilde Healthcare Partners has bought a majority stake in specialist virology CRO Viroclinics Biosciences in a transaction prompted by growing global demand for virus research services and vaccines.
Drugmakers and academics will have to upload the results of trials run in Europe to a public database under a provisional deal agreed in the European Parliament earlier today.
Genae Associates has expanded its European reach by opening an office in Switzerland to offer clinical trials and research projects relating to medical devices.
Algorithme Pharma has increased early stage patient access by teaming with a Montreal hospital, and says it provides a breadth of therapeutic areas not normally associated with mid-sized CROs.
Italian CRO Centro Ricerche Cliniche di Verona (CRC) has become the first firm to be awarded a new early phase accreditation from the European CROs Federation (EUCROF).
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
Strategic partnerships are “the next phase” of sponsor-CRO relations, according to Parexel, and on top of saving pharma on oversight costs will reshape the industry.
Smartphones are changing the role of the patient in clinical trials and can be used for industry success, Pfizer and technology provider firm Exco InTouch said at PCT 2013.
Economic uncertainty and a bleak fiscal outlook will lead to over-regulation and increased fines in the clinical trial industry, according to an economic expert at PCT.
Strategic partnerships were put on trial yesterday at PCT and with a number of alliances coming up for renewal, Pfizer, Novartis, Amgen and Baxter spoke about the issues affecting a sponsor-CRO relationship.
India’s CDSCO has unveiled a list of clinical trial regulations that does little to explain how they will fix a system that has seen an increasing number of companies pulling their operations from the country.
Plagued with tighter deadlines and calls for more efficiency, CROs (contract research organizations) seem to be increasingly turning to apps and cloud-based systems to develop CTMS (clinical trial management system) modules.
After almost two years of lagging early phase clinical research work, it seems some CROs are now seeing an uptick in specialized trials that require more scientific expertise.
CRO Parexel’s stock fell to a four-month low and continued to hover around that level late last week following concerns about low bookings and increased competition in the first quarter of 2014.
Quintiles issued a mixed set of revised financial predictions for 2013, increasing its earnings per share forecast after a surge of new business wins and narrowing its service revenue.
inVentiv Health has opened a new UK office in order to better target European customers, whilst Novum says its North Dakota facility will strengthen its offerings.
Despite a strong Q3, Icon has outlined plans for further cuts at its UK clinical pharmacology unit (CPU) as it rejigs its ‘weak’ early phase services business.
Early stage drug developer Charles River Laboratories is pushing further into Asia with its purchase of the microbiology subcontractor BRASS Pte Ltd. Terms of the acquisition were not disclosed.
Yale University’s Cardiovascular Research Group (YCRG) and medical device CRO genae associates nv, have announced a collaboration and co-marketing agreement for cardiovascular devices.
CRO Quintiles has decided to close its Phase I unit in Hyderabad, India, because of a “challenging external business environment,” a company spokesman told us.
Parexel has teamed up with Japanese trial management services firm Fuijitsu Systems West in an agreement that underlines the CROs eClinical growth ambitions in Asia.
CRO Quintiles says it is in favor of the voluntary sharing of de-identified and masked clinical and preclinical data that protects the interests of research participants and proprietary data, though it stopped short of calling for the public release of...
Cromsource has opened offices in Paris in response to the growth of pharma R&D which is flourishing under French Government incentives, the company says.
CRO Covance has launched an external laboratory management service offering for biopharmaceutical sponsors looking to external lab testing for its clinical trials.
